Core Insights - SOTON Development (603612.SH) reported its Q3 2025 results, revealing that 17 institutional investors hold a total of 55.8463 million shares, representing 11.21% of the company's total equity [1] - The top ten institutional investors collectively own 10.77% of the shares, with a decrease of 1.83 percentage points compared to the previous quarter [1] Institutional Holdings - Among public funds, one fund, CITIC Securities Rui Li A, increased its holdings slightly, while seven funds, including Guotai Junan Value Advantage Flexible Allocation Mixed Fund, reduced their holdings by 1.18% [2] - Three new public funds disclosed their holdings in SOTON Development, while 230 funds did not disclose their holdings this quarter, including notable funds like Southern CSI 1000 ETF and Harvest New Energy New Materials Stock A [2] Social Security Fund - One new social security fund, the National Social Security Fund 502 Portfolio, disclosed its holdings in SOTON Development this quarter [2]

Core Viewpoint - Jinpai Home (603180.SH) reported its Q3 2025 results, highlighting a total institutional ownership of 70.12 million shares, accounting for 45.46% of the company's total equity, with a slight decrease of 1.00 percentage points from the previous quarter [1] Institutional Investors - Three institutional investors disclosed their holdings in Jinpai Home, including Xiamen Jianpan Group Co., Ltd., China Minsheng Bank Co., Ltd. - Everbright Baodexin Credit Enhancement Bond Fund, and Agricultural Bank of China Co., Ltd. - ICBC Credit Suisse Strategic Transformation Theme Equity Fund [1] - The total institutional ownership decreased by 1.00 percentage points compared to the last quarter [1] Public Funds - One public fund, Everbright Baodexin Credit Enhancement Bond Class A, reported a decrease in holdings compared to the previous quarter [1] - A total of 45 public funds that did not disclose their holdings this quarter include notable funds such as Huatai-PineBridge Advantage Selection Mixed Fund, China Merchants Zhongzheng Consumer Leader Index Enhanced A, and others [1] Social Security Funds - One social security fund, the National Social Security Fund 103 Portfolio, did not disclose its holdings this quarter [1]

Core Insights - On October 24, Xingsen Technology's stock rose by 5.3%, reaching a price of 20.05 CNY per share, with a trading volume of 620 million CNY and a turnover rate of 2.09%, resulting in a total market capitalization of 34.078 billion CNY [1] Company Overview - Shenzhen Xingsen Quick Circuit Technology Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on March 18, 1999, with its IPO on June 18, 2010 [1] - The company's main business includes PCB (Printed Circuit Board) and semiconductor operations, with revenue composition as follows: PCB business 71.45%, IC packaging substrate 21.09%, other 4.29%, and semiconductor testing board 3.17% [1] Shareholder Analysis - Among the top ten circulating shareholders of Xingsen Technology, a fund under Everbright Pramerica Asset Management holds a significant position. The Everbright Pramerica Credit Enhancing Bond A Class Fund (360013) reduced its holdings by 10.646 million shares in Q2, retaining 11.2931 million shares, which accounts for 0.75% of the circulating shares [2] - The fund has achieved a year-to-date return of 20.86%, ranking 57 out of 6231 in its category, and a one-year return of 28.41%, ranking 22 out of 6005 [2] Fund Management - The fund manager of Everbright Pramerica Credit Enhancing Bond A Class Fund is Huang Bo, who has been in the position for 6 years and 18 days. The fund's total asset size is 14.614 billion CNY, with the best return during his tenure being 89.13% and the worst being 10.02% [3]

Group 1 - The core viewpoint of the news is that Baicheng Pharmaceutical (301096.SZ) reported its semi-annual results for 2025, revealing significant institutional investor activity and changes in shareholding [1] - As of August 27, 2025, a total of 10 institutional investors disclosed holdings in Baicheng Pharmaceutical A-shares, with a combined holding of 14.74 million shares, accounting for 13.50% of the total share capital [1] - The top ten institutional investors include various management partnerships and funds, with their combined holding percentage decreasing by 1.07 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Rongtong Health Industry Flexible Allocation Mixed A/B, reported a slight decrease in holdings compared to the previous quarter [2] - Two new public funds were disclosed during this period, namely Caitong Technology Innovation Mixed A and Caitong Fusheng Mixed Initiation (LOF) A [2] - Two public funds, including Everbright Baodexin Credit Enhancement Bond Class A and Everbright Baodexin Anqi Bond Class A, were not disclosed in this period compared to the previous quarter [2]

Group 1 - The core viewpoint of the news is that Jianfan Bio (300529.SZ) reported a decrease in institutional investor holdings in its A-shares, with a total of 51.87 million shares held by six institutions, representing 6.49% of the total share capital, down by 2.00 percentage points from the previous quarter [1] Group 2 - In the public fund sector, two public funds increased their holdings, including Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with an increase ratio of 0.25% [2] - Two public funds decreased their holdings, namely, Zhaoshang Guozhen Biomedical Index A and Yifangda Growth Enterprise ETF, with a decrease ratio of 0.11% [2] - Six public funds did not disclose their holdings in the current period, including Guangda Baodexin Credit Enhancement Bond A and others [2] Group 3 - Regarding foreign investment, the Hong Kong Central Clearing Limited is noted as an institution that did not disclose its holdings in the current period [3]